Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC)

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 4, 2010, Pages 1115-1118

  Yan, Peng Wei ^a,b   Huang, Xin En ^a,b   Jiang, Yong ^a,b   Tang, Jin Hai ^a   Xu, Hong Xia ^a   Xu, Xia ^a   Jin, Xiang ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Breast cancer; Epirubicin; FEC; Vinorelbine

Indexed keywords

EID: 78650680975     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Baldini E, Tibaldi C, Chiavacci F, et al (1998). Epirubicin/vinorelbine as first line therapy in metastatic breast cancer. Breast Cancer Res Treat, 49, 129-34.
2. Blomqvist C, Hietanen P, Teerenhovi L, et al (1995). Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Eur J Cancer, 31A, 2406-8.
3. Bruno S, Puerto VL, Mickiewicz E, et al (1995). Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol, 18, 392-6.
4. Early Breast Cancer Trialists' Collaborative Group (1998). Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet, 352, 930-42.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 365, 1687-717.
6. Ejlertsen B, Mouridsen HT, Langkjer ST, et al (2004). Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol, 22, 2313-20.
7. Elling D, Eggemann H, Kümmel S, et al (2003). Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study. Breast, 12, 208-11.
8. Fumoleau P, Delgado FM, Delozier T, et al (1993). Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol, 11, 1245-52.
9. Garcia-Conde J, Lluch A, Martin M et al (1994). Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol, 5, 854-7.
10. Goldhirsch A, Glick JH, Gelber RD, et al (2005). Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol, 16, 1569-83.
11. Huang O, Chen CM, Wu JY, et al (2009). Study on predictors of long term results for neo-adjuvant chemotherapy in locally advanced breast cancer. Zhonghua Wai Ke Za Zhi, 47, 511-15.
12. Levine MN, Bramwell VH, Pritchard KI, et al (1998). Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 16, 2651-8
13. Levine MN, Pritchard KI, Bramwell VH, et al (2005). Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol, 23, 5166-70.
14. Martín M, Rodríguez-Lescure A, Ruiz A, et al (2008). Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst, 100, 805-14.
15. Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14.
16. Nisticò C, De Matteis A, Rossi E, et al (2005). Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer. Anticancer Res, 25, 1343-8.
17. Pierre Fumoleau, Pierre Kerbrat, Pascale Romestaing, et al (2003). Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol, 21, 298-305.
18. Romero A, Rabinovich MG, Vallejo CT, et al (1994). Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol, 12, 336-41.
19. Twelves CJ, Dobbs NA, Curnow A, et al (1994). A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer, 70, 990-3.
20. Terenziani M, Demicheli R, Brambilla C, et al (1996). Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat, 39, 285-91
21. Vogel C, O'Rourke M, Winer E, et al (1999). Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol, 10, 397-402.
22. Vici P, Colucci G, Gebbia V, et al (2002). First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol, 20, 2689-94.
23. Weber BL, Vogel C, Jones S, et al (1995). Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol, 13, 2722-30.